# reload+after+2024-01-23 14:43:43.202571
address1§455 Grand Union Boulevard
city§Somerville
state§MA
zip§02145
country§United States
phone§339 499 9300
website§https://www.bluebirdbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
fullTimeEmployees§323
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Andrew  Obenshain', 'age': 49, 'title': 'President, CEO & Director', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1041870, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas J. Klima', 'age': 51, 'title': 'Chief Commercial Officer & COO', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 654969, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard A. Colvin M.D., Ph.D.', 'age': 57, 'title': 'Chief Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 696239, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher  Krawtschuk CPA', 'age': 49, 'title': 'CFO, Principal Accounting Officer & Treasurer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph D. Vittiglio Esq., J.D.', 'age': 51, 'title': 'Chief Legal & Business Officer and Secretary', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Jess  Rowlands', 'title': 'Head of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Andrea  Walton', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kasra  Kasraian', 'title': 'Senior Vice President of Technical Development & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott  Shoemaker', 'title': 'Senior Vice President of Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sarah  Alspach', 'title': 'Senior Vice President of External Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§3
compensationRisk§4
shareHolderRightsRisk§5
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.866
priceToSalesTrailing12Months§12.597516
currency§USD
dateShortInterest§1702598400
forwardEps§-1.77
pegRatio§-0.02
exchange§NMS
quoteType§EQUITY
shortName§bluebird bio, Inc.
longName§bluebird bio, Inc.
firstTradeDateEpochUtc§1371648600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§1b3e1ee9-bff8-3431-9ea6-b181365ba65f
gmtOffSetMilliseconds§-18000000
targetHighPrice§13.0
targetLowPrice§2.0
targetMeanPrice§5.62
targetMedianPrice§5.0
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§12
quickRatio§1.241
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
